Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.

Butler, Javed; Siddiqi, Tariq Jamal; Filippatos, Gerasimos; Ferreira, João Pedro; Pocock, Stuart J; Zannad, Faiez; Anker, Stefan D; (2022) Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. European Journal of Heart Failure, 24 (2). pp. 245-248. ISSN 1388-9842 DOI: https://doi.org/10.1002/ejhf.2420

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1002/ejhf.2420

Abstract

Item Type Article
Faculty and Department Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID 34989083
Elements ID 169561

Share

Download

Embargo Date: 5 January 2023

Restricted to: Repository staff only

Filename: Butler-etal_2022_Early-Benefit-with-Empagliflozin-in-Heart-Failure.pdf

Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

[img]

Downloads

View details

Metrics & Citations


Google Scholar